{"id":180541,"date":"2026-02-12T23:39:24","date_gmt":"2026-02-13T04:39:24","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180541"},"modified":"2026-02-12T23:39:24","modified_gmt":"2026-02-13T04:39:24","slug":"zim-laboratories-q3fy26-profit-rebounds-on-export-led-growth-margins-steady-amid-ongoing-remediation-and-rd-push","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/zim-laboratories-q3fy26-profit-rebounds-on-export-led-growth-margins-steady-amid-ongoing-remediation-and-rd-push\/","title":{"rendered":"ZIM Laboratories Q3FY26 profit rebounds on export-led growth; margins steady amid ongoing remediation and R&amp;D push"},"content":{"rendered":"\n<p>ZIM Laboratories Limited (NSE:ZIMLAB), an India-based pharmaceutical formulations and nutraceutical company focused on oral thin films (OTF), innovative drug delivery technologies and branded\/generic formulations for regulated and emerging markets, reported improved quarterly performance for Q3FY26, supported by export-led growth, recovery in profitability and higher contribution from nutraceuticals and innovative products.<\/p>\n\n\n\n<p>Nine-month earnings remained under pressure due to margin contraction and regulatory remediation investments, even as the company advanced its product pipeline and expansion initiatives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Financial Performance: Q3FY26 and 9MFY26<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Total operating income rose 12.8% year-on-year to \u20b91,087 million in Q3FY26, driven by improved sales momentum and higher exports.<ul><li>EBITDA grew 9.1% YoY to \u20b9145 million, with margins at 13.4%.<\/li><\/ul>\n<ul class=\"wp-block-list\">\n<li>Profit after tax stood at \u20b944 million, supported by higher revenue and operating leverage.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>For 9MFY26, operating income remained largely flat at \u20b92,691 million compared with \u20b92,703 million in the previous year.<ul><li>EBITDA declined 15.5% YoY to \u20b9280 million, with margins narrowing to 10.4%, reflecting investments in remediation, regulatory filings and R&amp;D.<\/li><\/ul>\n<ul class=\"wp-block-list\">\n<li>Net profit for the nine-month period fell to \u20b921 million from \u20b973 million a year earlier.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Segment Performance &amp; Business Mix<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pharmaceutical formulations continued to dominate the revenue mix, contributing 72% of Q3FY26 revenue at \u20b9786 million, while nutraceuticals accounted for 28% at \u20b9300 million.<\/li>\n\n\n\n<li>The nutraceutical business witnessed strong growth, rising 93% quarter-on-quarter and 34% year-on-year, aided by resolution of currency issues in legacy markets.<\/li>\n\n\n\n<li>Exports remained the key growth driver, accounting for 88% of revenue in Q3FY26, reflecting a 23% YoY increase.<\/li>\n\n\n\n<li>In 9MFY26, export revenue stood at \u20b92,290 million, representing 85% of total income.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Business &amp; Operations Update<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The company reported substantial progress on its corrective and preventive action (CAPA) remediation plan, with most initiatives implemented and facilities expected to be inspection-ready by March 2026.<\/li>\n\n\n\n<li>Investments were made in automation, equipment upgrades and alternative manufacturing arrangements to support regulatory compliance and operational continuity.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>R&amp;D &amp; Innovation Initiatives<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher R&amp;D investments:<\/strong> \u20b9230 Mn spent in 9MFY26 (8.6% of operating income) and \u20b975 Mn in Q3FY26, focused on product development, dossier upgrades and regulatory filings.<\/li>\n\n\n\n<li><strong>Advancing Innovative Product Pipeline (NIP + OTF):<\/strong> rose 63% sequentially to \u20b9132 million in Q3FY26, supported by ongoing registrations and product development across regulated markets including Europe and the UK.<\/li>\n\n\n\n<li><strong>Bioequivalence (BE) studies &amp; regulatory filings:<\/strong> \u20b974 Mn allocated in 9MFY26 to accelerate commercialization of new formulations.<\/li>\n\n\n\n<li><strong>Expanded technology platforms:<\/strong> Continued investment in versatile drug-delivery technologies, especially oral thin films and differentiated formulations.<\/li>\n\n\n\n<li><strong>Pipeline expansion across therapy areas:<\/strong> Products under development include CNS, gastrointestinal, urology, analgesic and anti-infective segments, targeting regulated markets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Other Major Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In Q3FY26, \u20b9157 million was added to the gross block toward expansion and registrations, while \u20b9229 million was invested during the nine-month period, including spending on bioequivalence studies and regulatory filings.<\/li>\n\n\n\n<li>The company also expanded its leadership team and strengthened regulatory, quality and operations capabilities to support global compliance and commercialization efforts.<\/li>\n\n\n\n<li>ZIM announced plans for dedicated facilities for key products and nutraceutical formulations targeting global markets.<\/li>\n\n\n\n<li>The board approved a preferential issue of shares to raise up to \u20b935 crore to fund expansion, remediation and growth initiatives.<\/li>\n<\/ul>\n\n\n\n<p><a href=\"https:\/\/drive.google.com\/file\/d\/1mvvhYfUx1X5QeF9sYiGjl43IV7zB-iCR\/view?usp=sharing\" target=\"_blank\" rel=\"noopener\">https:\/\/drive.google.com\/file\/d\/1mvvhYfUx1X5QeF9sYiGjl43IV7zB-iCR\/view?usp=sharing<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Market Perspective &amp; Outlook<\/strong> <\/h2>\n\n\n\n<p>Management remains focused on expanding exports, advancing innovative formulations and completing regulatory remediation. Upcoming inspections and product registrations are expected to support growth recovery in FY27. Continued investment in R&amp;D, manufacturing upgrades and new market entries is likely to strengthen long-term competitiveness, although near-term profitability may remain sensitive to compliance costs and operating investments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ZIM Laboratories Limited (NSE:ZIMLAB), an India-based pharmaceutical formulations and nutraceutical company focused on oral thin films (OTF), innovative drug delivery technologies and branded\/generic formulations for regulated and emerging markets, reported improved quarterly performance for Q3FY26, supported by export-led growth, recovery in profitability and higher contribution from nutraceuticals and innovative products. Nine-month earnings remained under pressure [&hellip;]<\/p>\n","protected":false},"author":2378,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,5747],"tags":[2132,10162,16390],"class_list":["post-180541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-manufacturing","tag-pharmaceutical","tag-zimlab"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":153852,"url":"https:\/\/alphastreet.com\/india\/zim-laboratories-ltd-q1fy24-96-fall-in-profits\/","url_meta":{"origin":180541,"position":0},"title":"Zim Laboratories Ltd Q1FY24; 96% fall in Profits","author":"Chirag Gupta","date":"August 14, 2023","format":false,"excerpt":"Zim Laboratories Limited is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The company also has wholly owned subsidiaries present overseas which are engaged in the manufacturing & wholesale of pharmaceutical products, market research and research\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1054.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":176124,"url":"https:\/\/alphastreet.com\/india\/zim-laboratories-ltd-zimlab-q4-2025-earnings-call-transcript\/","url_meta":{"origin":180541,"position":1},"title":"Zim Laboratories Ltd (ZIMLAB) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Zim Laboratories Ltd (NSE: ZIMLAB) Q4 2025 Earnings Call dated May. 22, 2025 Corporate Participants: Unidentified Speaker Anwar S. Daud Shyam Mohan Patro Chandrashekhar Mainde Zulfiquar Kamal \u2014 Zim Laboratories Ltd Zain Daud \u2014 Investor Relations Incharge Analysts: Unidentified Participant Deepika Sharma \u2014 Analyst Dhwanil Desai \u2014 Analyst Ankit Gupta\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178821,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-reports-16-net-profit-growth-in-q3fy26\/","url_meta":{"origin":180541,"position":2},"title":"Sun Pharmaceutical Industries Reports 16% Net Profit Growth in Q3FY26","author":"Staff Correspondent","date":"February 2, 2026","format":false,"excerpt":"On January 31, 2026, Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) reported a net profit of Rs. 33,688 million for the third quarter ended December 31, 2025, a 16.0% increase year-over-year. Consolidated sales reached Rs. 154,691 million, supported by a 16.2% increase in Indian formulation sales and growth in\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172961,"url":"https:\/\/alphastreet.com\/india\/ipca-laboratories-q2-fy26-earnings-results\/","url_meta":{"origin":180541,"position":3},"title":"Ipca Laboratories Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 9, 2025","format":false,"excerpt":"Ipca Laboratories Ltd, engaged in manufacturing and marketing of pharmaceuticals, reported robust financial performance for Q2FY26 with revenue growth across domestic formulations, exports, and APIs. Financial Highlights: Revenues increased 8.54% year-on-year to \u20b92,556 crore from \u20b92,355 crore, with domestic formulations up 8% to \u20b91,019 crore and exports up 7% to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/IPCA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179824,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-reports-q3fy26-with-revenue-growth-and-ebitda-margin-expansion\/","url_meta":{"origin":180541,"position":4},"title":"Marksans Pharma Reports Q3FY26 with Revenue Growth and EBITDA Margin Expansion","author":"Staff Correspondent","date":"February 6, 2026","format":false,"excerpt":"About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health,\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177861,"url":"https:\/\/alphastreet.com\/india\/granules-india-q3-fy26-earnings-results\/","url_meta":{"origin":180541,"position":5},"title":"Granules India Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 27, 2026","format":false,"excerpt":"Executive Summary Granules India Ltd reported Q3FY26 revenues of \u20b91,388 crore, up 21.97% YoY, with consolidated net profit rising 27.12% to \u20b9150 crore. Total expenses increased 19.37% YoY to \u20b91,183 crore, reflecting efficient cost management amid strong revenue growth. Revenue & Growth Revenues grew to \u20b91,388.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/G-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2378"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180541"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180541\/revisions"}],"predecessor-version":[{"id":180544,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180541\/revisions\/180544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}